Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL 

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma. 

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

OncLive App

Interactive Tools

Biomarker Consortium

Subscribe

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.

Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs

 team as an assistant editor in 2025 after previously working on the 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

The OncLive Insider app is live!

CME Opportunities

Specialty

OncLive Insights

Integrating Novel Therapies into Treatment of B-Cell Malignancies

Videos

Changing Treatment Landscape in CLL

Role of B-Cell Receptor Signaling Inhibitors in CLL

Preventing Infusion Reactions With CD20 Antibodies in CLL

Ibrutinib Monotherapy and Combinations in CLL

Ibrutinib-Associated Adverse Events

Emerging Strategies in CLL and Follicular Lymphoma 

B-Cell Receptor Inhibitor Response Criteria in CLL

Ibrutinib in WaldenstrÃ¶m's Macroglobulinemia

Frontline Treatments for Follicular Lymphoma

Stem Cell Transplantation in Follicular Lymphoma

Management of Refractory Follicular Lymphoma

Diffuse Large B-Cell Lymphoma Treatment Regimens

Treating Relapsed Diffuse Large B-Cell Lymphoma

Upfront Treatments for Mantle Cell Lymphoma

Treatments for Relapsed Mantle Cell Lymphoma

Non-Intensive Treatments for Mantle Cell Lymphoma

Integrating Novel Therapies into Treatment of B-Cell Malignancies

Latest Conference Coverage